Ann: Invex Granted Type C Meeting with FDA, page-26

Re: bariatric surgery - agree that it doesn't change the investment thesis. It's not a permanent solution for most patients: ~50% regain the weight within 2 years of surgery.

I was also recently reviewing the side effects of acetazolamide (see article, The Idiopathic Intracranial Hypertension TreatmentTrial: A Review of the Outcomes, 2017) - paresthesias, dysgeusia (i.e., altered perception of taste), gastrointestinal upset (i.e., vomitting, diarrhoea), urinaryfrequency, and fatigue, and less commonly, metabolic acidosis, hypokalemia, Stevens–Johnsonsyndrome, and blood dyscrasias. Less than 50% of the 86 pts randomised to active drug therapy tolerated the maximum dose (4 g/ day). 9 SAEs were reported, with 3 directly related to the study drug.

The market is wide open for Presendin. We just need to get some good news from the FDA and get the formulation and dosage right and we're set.